This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Understanding the impact of 6 reported cases of inflammation in patients receiving Syfovre injections

Ticker(s): APLS, ISEE

Who's the expert?

Institution: Retina Associates of New York

  • Private practice ophthalmologist who also trains doctors at the New York Eye and Ear Infirmary of Mount Sinai.
  • Currently manages between 200-300 patients with wet-AMD and 200 with geographic atrophy.
  • Has authored multiple peer-reviewed publications, including research on macular degeneration, diabetic retinopathy, macular pucker, and unusual diseases of the retina.

Interview Questions
Q1.

Please describe your background and practice setting

Added By: ben_admin
Q2.

How many patients with geographic atrophy do you manage?

Added By: ben_admin
Q3.

Have you prescribed Syfovre? If so, have any patients experienced inflammation?

Added By: ben_admin
Q4.

What impact does the 6 cases of inflammation have on your prescribing habits of Syfovre moving forward?

Added By: ben_admin
Q5.

What rate of occlusive retinal vasculitis is acceptable in your mind for these patients?

Added By: ben_admin
Q6.

How likely is it in your view that all 6 cases were the result of Syfovre's mechanism of action versus some other cause?

Added By: userfe9ad41d

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.